Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) just unveiled an update.
Percheron Therapeutics has notified the ASX of its intention to issue up to 13,750,000 new unquoted options as part of a placement or similar capital initiative. The options will have an exercise price of A$0.01 and a two-year term from the issue date, with issuance targeted for April 15, 2026.
The proposed securities issuance signals a move to strengthen Percheron Therapeutics’ capital structure and potential funding flexibility without immediately diluting existing shareholders. By using low‑exercise‑price unquoted options, the company may incentivize stakeholders and align longer-term interests with its future operational and development milestones.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australia-based company listed on the ASX under the ticker PER. The firm operates in the therapeutics sector, focusing on the development of pharmaceutical or biotech treatments, although specific product programs or therapeutic areas are not detailed in the filing.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.07M
For an in-depth examination of PER stock, go to TipRanks’ Overview page.